A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer

Min-Hee Ryu, Baek-Yeol Ryoo, Tae Won Kim, Sung Bae Kim, Hyeong-Seok Lim, Kyun-Seop Bae, Sook Ryun Park, Yeong-Woo Jo, Hyun Ju Cho, Yoon-Koo Kang, Min-Hee Ryu, Baek-Yeol Ryoo, Tae Won Kim, Sung Bae Kim, Hyeong-Seok Lim, Kyun-Seop Bae, Sook Ryun Park, Yeong-Woo Jo, Hyun Ju Cho, Yoon-Koo Kang

Abstract

Lessons learned: Ideally, patients should have access to an oral formulation of paclitaxel, as well as an intravenous formulation, to allow development of regimens exploring alternate schedules and to avoid reactions to Cremophor EL (BASF Corp., Ludwigshafen, Germany, https://www.basf.com).DHP107 is a novel oral paclitaxel formulation that is a tolerable and feasible regimen for patients with gastric cancer, with data suggesting efficacy similar to that of intravenous paclitaxel.

Background: We evaluated the maximum tolerated dose (MTD) of DHP107, a novel oral paclitaxel formulation, and the efficacy and safety of the agent in patients with advanced solid tumors.

Patients and methods: Phase I study: cohorts of 3-6 patients with advanced solid tumors received escalating DHP107 doses. Phase IIa study: patients with measurable advanced gastric cancer received DHP107, 200 mg/m2 b.i.d., on days 1, 8, and 15 every 4 weeks. Pharmacokinetics, safety, and efficacy were analyzed.

Results: Phase I: 17 patients received a dose-escalating regimen of DHP107, 150-250 mg/m2 b.i.d. Dose-limiting toxicities were neutropenia and febrile neutropenia. The MTD (recommended dose) for phase IIa was 200 mg/m2 b.i.d. Phase IIa: 11 patients with measurable advanced gastric cancer in whom first-line therapy failed received DHP107 (MTD). Three confirmed partial responses were observed. Median progression-free survival of gastric cancer patients (n = 16) treated at the MTD was 2.97 (95% confidence interval, 1.67-5.40) months (Fig. 1). The most frequent grade 3/4 adverse events were neutropenia (35.3%) and leukopenia (17.6%) at the MTD (phase I and IIa combined; n = 17).

Conclusion: DHP107 showed good antitumor efficacy and was tolerable. The MTD (200 mg/m2 b.i.d.) is recommended for use in further studies comparing DHP107 with standard intravenous paclitaxel therapy. The Oncologist 2017;22:129-e8.

Trial registration: ClinicalTrials.gov NCT02890511.

© AlphaMed Press; the data published online to support this summary is the property of the authors.

Figures

Figure 1.
Figure 1.
Kaplan‐Meier curve for progression‐free survival in patients with gastric cancer in the efficacy‐evaluable population (n = 16). These were patients with gastric cancer.
Figure 2.
Figure 2.
Plasma concentration of paclitaxel after oral administration of DHP107.

References

    1. Vergote I, Tropé CG, Amant F et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943–953.
    1. Kang HJ, Chang HM, Kim TW et al. A phase II study of paclitaxel and capecitabine as a first‐line combination chemotherapy for advanced gastric cancer. Br J Cancer 2008;98:316–322.
    1. Di Leo A, Gomez HL, Aziz Z et al. Phase III, double‐blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first‐line treatment for metastatic breast cancer [published correction appears in J Clin Oncol 2009;27:1923]. J Clin Oncol 2008;26:5544–5552.
    1. Sandler A, Gray R, Perry MC et al. Paclitaxel‐carboplatin alone or with bevacizumab for non‐small‐cell lung cancer [published correction appears in N Engl J Med 2007;356:318]. N Engl J Med 2006;355:2542–2550.
    1. Sparreboom A, Van Asperen J, Mayer U et al. Limited oral bioavailability and active epithelial secretion of paclitaxel (Taxol) caused by p‐glycoprotein in the intestine. Proc Natl Acad Sci USA 1997;94:2031–2035.
    1. Rowinsky EK, Wright M, Monsarrat B et al. Clinical pharmacology and metabolism of Taxol (paclitaxel): Update 1993. Ann Oncol 1994;5(suppl 6):S7–S16.
    1. Sonnichsen DS, Liu Q, Schuetz EG et al. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995;275:566–575.
    1. Walle T, Walle K, Kumar GN et al. Taxol metabolism and disposition in cancer patients. Drug Metab Dispos 1995;23:506–512.
    1. Weiss RB, Donehower RC, Wiernik PH et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263–1268.
    1. Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 1995;3:16–23.
    1. Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180–190.
    1. Malingré MM, Beijnen JH, Rosing H et al. A phase I and pharmacokinetic study of bi‐daily dosing of oral paclitaxel in combination with cyclosporin A. Cancer Chemother Pharmacol 2001;47:347–354.
    1. Malingré MM, Beijnen JH, Rosing H et al. Co‐administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 2001;84:42–47.
    1. Binkhathlan Z, Lavasanifar A. p‐glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: Current status and future perspectives. Curr Cancer Drug Targets 2013;13:326–346.
    1. Hong JW, Lee IH, Kwak YH et al. Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation. Mol Cancer Ther 2007;6:3239–3247.
    1. Na YS, Jung KA, Yang SJ et al. Antitumor effects of oral paclitaxel DHP107 on gastric cancer xenografts. Cancer Res 2011;71(suppl 8):2539.
    1. Hong YS, Kim KP, Lim HS et al. A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: Crossover comparisons with intravenous paclitaxel. Invest New Drugs 2013;31:616–622.
    1. Hironaka Y, Zenda S, Boku N et al. Weekly paclitaxel as second‐line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006;9:14–18.
    1. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–247.
    1. Jang Y, Jo YW, Lee H et al. Absorption profiles of an oral paclitaxel formulation, DHP107 with variable dosing intervals in mice. Abstract presented at the 40th Annual Meeting and Exposition of the Controlled Release Society; July 21–24, 2013; Hawaii Convention Center, Honolulu, Hawaii. Available at . Accessed [DATE].
    1. Simon R. Optimal two‐stage designs for clinical trials. Control Clin Trials 1989;10:1–10.
    1. Kodera Y, Ito S, Mochizuki Y et al. A phase II study of weekly paclitaxel as second‐line chemotherapy for advanced gastric cancer (CCOG0302 Study). Anticancer Res 2007;27:2667–2671.
    1. Liebmann JE, Cook JA, Lipschultz C et al. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 1993;68:1104–1109.
    1. Raymond E, Hanauske A, Faivre S et al. Effects of prolonged versus short‐term exposure paclitaxel (Taxol) on human tumor colony‐forming units. Anticancer Drugs 1997;8:379–385.
    1. Jurado JM, Sánchez A, Pajares B et al. Combined oral cyclophosphamide and bevacizumab in heavily pre‐treated ovarian cancer [published correction appears in Clin Transl Oncol 2008;10:772]. Clin Transl Oncol 2008;10:583–586.
    1. Garcia AA, Hirte H, Fleming G et al. A trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76–82.
    1. Pasquier E, Kavallaris M, André N. Metronomic chemotherapy: New rationale for new directions. Nat Rev Clin Oncol 2010;7:455–465.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe